A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.

ABSTRACT:

Background

Despite evidence indicating the dominance of cell-of-origin signatures in molecular tumor patterns, translating these genome-wide patterns into actionable insights has been challenging. This study introduces breast cancer cell-of-origin signatures that offer significant prognostic value across all breast cancer subtypes and various clinical cohorts, compared to previously developed genomic signatures.

Methods

We previously reported that triple hormone receptor (THR) co-expression patterns of androgen (AR), estrogen (ER), and vitamin D (VDR) receptors are maintained at the protein level in human breast cancers. Here, we developed corresponding mRNA signatures (THR-50 and THR-70) based on these patterns to categorize breast tumors by their THR expression levels. The

SUBMITTER: Omar M 

PROVIDER: S-EPMC11395215 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature